Salvia BioElectronics is developing MySalvia Therapy, an implantable neuromodulation system aimed at reducing the frequency and severity of chronic migraine attacks. The system uses two ultra-thin implants placed under the skin of the forehead and back of the head, activated on demand by an external wearable device, and is designed to be patient-controlled and minimally invasive. Salvia holds FDA Breakthrough Device Designation and is conducting the multi-center, double-blind, sham-controlled RECLAIM trial in Europe and Australia, with U.S. trials planned. The company says its approach targets patients who have not responded well to conventional therapies, addressing a large unmet need given migraine's substantial economic and disability burden. Salvia plans to use new capital to complete the RECLAIM study, pursue regulatory filings, and prepare for commercial launches in the United States, Europe, and Australia. It recently closed a $60M Series B to support those efforts, backed by a syndicate of investors. Salvia BioElectronics develops a neuromodulation platform that uses highly conforming bioelectronic foils designed to be inserted below the skin in a minimally invasive procedure to target known neural targets in chronic migraine. The company aims to translate proven neurostimulation therapy into an implantable form factor that is compatible with head anatomy, with the ambition of delivering a therapy as easy as taking medication and side-effect free. Salvia was founded in 2017 by neuromodulation industry veterans and is based in Eindhoven, the Netherlands. The startup emphasizes safety, effectiveness, affordability, and completing therapy development toward market entry. Management positions the approach as addressing an unmet need because there are currently no approved implantable devices for chronic migraine despite neurostimulation’s demonstrated effectiveness. The recent financing provides capital to advance product development and regulatory progress toward commercialization.

Total raised

$91M

Funding rounds

3

Latest round

Series B

Latest activity

May 2025